Sun Pharmaceutical Industries Makes History with $11.75 Billion Acquisition of Organon & Co.
On April 26, 2026, India’s Sun Pharmaceutical Industries made a groundbreaking announcement: the acquisition of New Jersey-based Organon & Co. This all-cash transaction, valued at $11.75 billion, sets a new record for the largest overseas acquisition by an Indian pharmaceutical company.
As per the definitive agreement, Sun Pharma will pay $14.00 per share for all outstanding shares of Organon. This represents a premium of more than 24% over the company’s closing price on April 24. The boards of both companies have approved the deal, which is expected to close in early 2027 pending regulatory approvals and shareholder consent.
Organon, a company specializing in women’s health and biosimilars, was spun off from Merck in 2021. It boasts a portfolio of over 70 products sold across 140 countries. For the year ended December 2025, Organon reported $6.2 billion in revenue. The combined entity is projected to generate $12.4 billion in revenue, which will position Sun Pharma among the top 25 global pharmaceutical companies. Furthermore, this acquisition will elevate Sun Pharma to a top-three player in global women’s health and mark its entry into biosimilars as a top-10 global player.
Following the announcement, Sun Pharma shares jumped more than 7% on Monday. The company plans to fund the acquisition through a combination of cash reserves and committed bank financing.
Source: CNBC